Citigroup Cuts Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $17.00

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target trimmed by Citigroup to $17.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the company. Stifel Nicolaus started coverage on Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $40.00 target price for the company. HC Wainwright restated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday. Jefferies Financial Group lowered their target price on shares of Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating on the stock in a research note on Monday. Cantor Fitzgerald lowered shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $28.11.

Eyepoint Pharmaceuticals Trading Down 14.3%

Shares of EYPT stock opened at $5.40 on Tuesday. The company has a market capitalization of $465.53 million, a P/E ratio of -1.44 and a beta of 1.76. The business’s 50 day moving average is $12.71 and its two-hundred day moving average is $13.44. Eyepoint Pharmaceuticals has a 12-month low of $3.95 and a 12-month high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The business had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. On average, research analysts predict that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EYPT. Janus Henderson Group PLC purchased a new position in Eyepoint Pharmaceuticals during the fourth quarter worth approximately $53,658,000. Commodore Capital LP acquired a new position in Eyepoint Pharmaceuticals during the first quarter worth $36,414,000. Paradigm Biocapital Advisors LP purchased a new stake in Eyepoint Pharmaceuticals in the 3rd quarter valued at $28,556,000. Orbimed Advisors LLC purchased a new stake in Eyepoint Pharmaceuticals in the 3rd quarter valued at $25,575,000. Finally, Suvretta Capital Management LLC grew its holdings in Eyepoint Pharmaceuticals by 26.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock valued at $143,012,000 after buying an additional 1,634,970 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Key Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Management has argued that the failed LUGANO Phase 3 trial may have been distorted by an anomalous group of nine patients—about 4% of participants—with vision loss unrelated to wet AMD. The company also highlighted favorable secondary endpoints and Duravyu’s potential durability advantages. Positive results from the upcoming LUCIA Phase 3 trial, expected in the fourth quarter of 2026, could help restore confidence in the program. EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
• Neutral Sentiment: Unusually heavy options activity indicates elevated trading and hedging interest, but does not establish a clear directional signal for EYPT. Eyepoint Pharmaceuticals Sees Unusually Large Options Volume
• Negative Sentiment: EyePoint is facing a shareholder investigation by SueWallSt over potential securities-law claims. Such notices can add legal uncertainty and further weigh on investor sentiment. EYPT Shareholder Investigation
• Negative Sentiment: Analyst sentiment has deteriorated following the trial result. Chardan Capital lowered its rating to Neutral, while Royal Bank of Canada cut EyePoint to Sector Perform and set a $5 price target. HC Wainwright, Cantor Fitzgerald, and JPMorgan maintained neutral-equivalent ratings, and Jefferies reduced its expectations. The broad lack of bullish ratings limits near-term valuation support. Chardan Capital Rating
• Negative Sentiment: The LUGANO Phase 3 failure caused a sharp sell-off because Duravyu did not meet its primary endpoint against Eylea. Analysts continue to view the result as a substantial risk to EyePoint’s pipeline and valuation, despite management’s explanation and the pending LUCIA data. EyePoint: Still A Sell After Phase 3 Crash

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.